OrbiMed’s Astria Therapeutics ATXS Stock Holding History

OrbiMed’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,400	Closed	-$184K	–	139
2020 Q1	$184K	Buy	+7,400	New	+$229K	﹤0.01%	140

Other funds holding ATXS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

OrbiMed's ATXS Position: Q2 2020 in Review

OrbiMed sold out of Astria Therapeutics (ATXS) in Q2 2020, closing a stake of 7,400 shares — an estimated $184K sold.

OrbiMed first reported a position in ATXS in Q1 2020 and held it in 1 quarter. The position peaked at $184K in Q1 2020. 50 funds tracked by Wall St. Rank hold ATXS as of Q2 2020.

OrbiMed reported no remaining Astria Therapeutics position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 7,400 Astria Therapeutics shares in Q2 2020, an estimated $184K.
OrbiMed first reported a position in Astria Therapeutics in Q1 2020 and held it in 1 quarter.
OrbiMed's Astria Therapeutics position peaked at $184K in Q1 2020.
50 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.